HOUSE BILL NO. HB0145

Pharmaceutical manufacturers-promotion of off label use.

Sponsored by: Representative(s) Clem, Barlow, Hallinan, Halverson, Jennings and Lone and Senator(s)
Bouchard

A BILL

for

1	AN ACT relating to food and drugs; allowing pharmaceutical
2	manufacturers to engage in truthful promotion of an off
3	label use of a drug, biological product or device;
4	specifying that truthful promotion of an off label use is
5	not misbranding; disallowing action by a licensing board
6	against a licensee solely for engaging in truthful
7	promotion or prescribing of an off label use of a drug,
8	biological product or device; specifying that this act does
9	not require a health care insurer to cover the cost of off
10	label use; specifying that the off label promotion or
11	prescribing of a drug does not create a cause of action;
12	providing definitions; and providing for an effective date.

13

14 Be It Enacted by the Legislature of the State of Wyoming:

15

```
1
        Section 1. W.S. 33-24-101(b) by creating a new
    paragraph (v), 35-7-110(a) by creating new paragraphs
2
3
    (xxxii) through (xxxiv) and by renumbering (xxxii) as
4
    (xxxv), 35-7-111 by creating a new subsection (d), 35-7-116
5
    and 35-7-118 by creating a new subsection (c) are amended
 6
    to read:
7
        33-24-101. Short title; definitions.
8
9
10
        (b) As used in this act:
11
12
             (v) "Misbranding" does not include the truthful
13
    promotion of an off label use of a drug, biological product
    or device as defined in W.S. 35-7-110(a)(xxxii) through
14
15
    (xxxiv).
16
17
        35-7-110. Definitions.
18
19
        (a) As used in this act:
20
21
             (xxxii) "Misbranding" does not include the
    truthful promotion of an off label use of a drug,
22
23
    biological product or device;
```

2018

1	
2	(xxxiii) "Off label use" means the use of a
3	United States food and drug administration approved drug,
4	biological product or device in a manner other than the use
5	the United States food and drug administration approved;
6	
7	(xxxiv) "Truthful promotion" means the sharing
8	between a pharmaceutical manufacturer and a licensed
9	professional who can prescribe medication within the
10	professional's scope of practice of information that is not
11	misleading, not contrary to fact and consistent with
12	generally accepted scientific principles;
13	
14	(xxxii) (xxxv) "This act" means W.S. 35-7-109
15	through 35-7-127.
16	
17	35-7-111. Prohibited acts.
18	
19	(d) The truthful promotion of an off label use of a
20	drug, biological product or device shall not be considered
21	a violation of this act.
22	

1	35-7-116. Food, drugs and cosmetics; adulteration and
2	misbranding.
3	
4	A food, cosmetic or a drug or device is adulterated if it
5	is adulterated under the federal act. A food, cosmetic or
6	a drug or device is misbranded if it is misbranded under
7	the federal act, except that the truthful promotion of an
8	off label use of a drug, biological product or device shall
9	not constitute misbranding.
10	
11	35-7-118. New drugs; off label use of approved drugs.
12	
13	(c) The truthful promotion of an off label use of an
14	existing approved drug shall not be considered a new drug.
15	The following shall apply:
16	
17	(i) A health care insurer may, but is not
18	required to, cover the cost of off label use of a drug,
19	biological product or device;
20	
21	(ii) No board or commission shall revoke, fail
22	to renew, suspend or take any other action against a
23	licensee, certificate holder or registrant based solely on

the person's truthful promotion or prescribing of an off 1 2 label use of a drug, biological product or device; 3 4 (iii) The off label truthful promotion or 5 prescribing of a drug, biological product or device shall 6 not create a cause of action against a pharmaceutical manufacturer or against any licensed professional who can 7 prescribe or dispense medication within the professional's 8 9 scope of practice, so long as the manufacturer or other 10 person's actions are not misleading, not contrary to fact 11 and consistent with generally accepted scientific 12 principles. 13 Section 2. This act is effective July 1, 2018. 14 15 16 (END)

5 HB0145

18LSO-0300